申请人:Glaxo Group Limited
公开号:US04918080A1
公开(公告)日:1990-04-17
The present invention provides ketones of the general formula (I): ##STR1## and physiologically acceptable salts and solvates thereof, wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a C.sub.1-6 alkyl group; Im represents an imidazolyl group of formula: ##STR2## wherein one of the groups represented by R.sup.3, R.sup.4 and R.sup.5 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenyl C.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; and an aromatic or heteroaromatic group as defined in the specification. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety and nausea and vomiting.
本发明提供了一般式(I)的酮类化合物:##STR1##和其生理上可接受的盐和溶剂物,其中R^1和R^2(可以相同也可以不同)分别表示氢原子或C1-6烷基;Im表示式的咪唑基:##STR2##其中由R^3、R^4和R^5表示的三个基中的一个是氢原子或C1-6烷基,C3-7环烷基,C3-6烯基,苯基或苯基C1-3烷基,而每个其他两个基(可以相同也可以不同)表示氢原子或C1-6烷基;以及在说明书中定义的芳香族或杂芳基团。这些化合物是5-HT3受体上5-HT效应的有效和选择性拮抗剂,并且可用于治疗精神疾病、焦虑和恶心呕吐等症状。